Middle East and Africa Cell and Gene Therapy Manufacturing Market: Industry Trends and Future Forecast, Till 2035 - Distribution by Type of Therapy, Type of Scale, Type of Workflow, Type of Process, Type of Technology, End User and Leading Players

The Middle East and Africa cell and gene therapy market is estimated to grow from USD 223 million in the current year to USD 848 million by 2035 at a CAGR of 16% during the forecast period.

Middle East and Africa Cell and Gene Therapy Manufacturing Market: Growth and Trends

Cell and gene therapies represent a class of advanced therapeutics demonstrating strong potential in the treatment of rare diseases, oncology indications, and chronic conditions. These therapies are strategically engineered to minimize off-target effects while enabling precise intervention at the cellular level. Key advantages include targeted therapeutic action, tissue regeneration and repair, the potential to slow or halt the progression of genetic disorders, and the ability to address specific genes that are dysfunctional or mutated.

The cell and gene therapy industry in the Middle East and Africa (MEA) is emerging as a high-growth sector, transitioning from nascent R&D to scaled manufacturing and clinical adoption through government-backed infrastructure and global partnerships. Current trends in the Middle East and Africa (MEA) cell and gene therapy manufacturing market emphasize rapid infrastructure expansion, automation adoption, and a surge in CDMO outsourcing, driven by clinical trial growth and government-backed biotech hubs. Owing to the abovementioned developments, the Middle East and Africa cell and gene therapy market is poised for notable future growth during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The market for cell and gene therapy in the Middle East and Africa (MEA) is expanding rapidly due to numerous factors such as demographic pressures (such as a growing population, increasing life expectancy), strategic government incentives, and technology development catered to local healthcare needs. One of the primary market growth drivers is the growing number of chronic illnesses, such as cancer, and uncommon genetic diseases that afflict millions of people. Other indications such as metabolic and ophthalmologic abnormalities require novel, one-time curative remedies that extend beyond traditional therapies. Based on the abovementioned factors, the MEA cell and gene therapy market is expected to witness sustained growth in the coming years.

Market Challenges: Critical Barriers Impeding Progress

Challenges persist in the cell and gene therapy market in the Middle East and Africa (MEA) despite the ongoing market growth, hindering faster adoption. High treatment costs, which are frequently unaffordable in environments with limited resources, restrict patient access. This worsens by the intricacy of customized manufacturing procedures that call for strict quality control for vectors, batch testing, and gene editing validation. Further, fragmented regulatory frameworks across diverse countries also create hurdles in approvals and standardization. Owing to these challenges, industry stakeholders have redirected their attention towards enhancing the manufacturing processes for cell and gene therapies.

Cell Therapies: Leading Market Segment

According to our estimates the production of cell therapies represents the biggest share (~60%) of the market. This is because of the increasing focus on developing cell-based therapies such as CAR-T cell treatments to tackle different diseases (especially cancer). Further, it is important to highlight that the gene therapies sector will demonstrate substantial growth opportunities and is expected to increase at a higher CAGR during the forecast period. Gene therapies have demonstrated strong efficacy in disease treatment and in slowing or halting disease progression, alongside increasing research focused on understanding genetic mutations and assessing the potential of gene-based interventions for effective disease management.

Research and Development: Dominating Market Segment

At present, the research and development sector leads the market, representing nearly 70% of the total share. Numerous factors, including a growing pipeline of cell and gene therapies along with heightened investments in research and development for large-scale production, drive the market share. However, the commercial-scale production segment is expected to grow at a higher CAGR throughout the forecast period. This can be attributed to the rising demand for the cell and gene therapies owing to the high prevalence of cancer, rare genetic disorders, and chronic diseases affecting millions in the region, necessitating scalable local production over reliance on imports.

Middle East and Africa Cell and Gene Therapy Manufacturing Market: Key Segments

Type of Therapy

• Cell Therapies (Stem Cell Therapy and Non-Stem Cell Therapy)
• Gene Therapies

Type of Scale

• Precommercial / R&D Scale Manufacturing
• Commercial Scale Manufacturing

Type of Workflow

• C Cell Processing
• Cell Banking
• Process Development
• Fill & Finish Operations
• Analytical & Quality Testing
• Raw Material Testing
• Vector Production
• Other Workflow

Type of Process

• Upstream Processes
• Downstream Processes

Type of Technology

• Fluorescence-Activated Cell Sorting (FACS)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Other Technologies

End User

• Pharmaceutical Companies
• Biopharmaceutical / Biotechnological Companies
• Contract Manufacturing Organizations

Example Players in the Middle East and Africa Cell and Gene Therapy Manufacturing Market

• Catalent
• Charles River Laboratories
• Lonza
• Merck
• Thermo Fisher Scientific
• WuXi AppTec

Key Questions Answered in this Report

• How many Middle East and Africa cell and gene therapy manufacturers are currently engaged in this market?
• Which are the leading companies in this market?
• Which country dominates the Middle East and Africa cell and gene therapy market?
• What are the key trends observed in the Middle East and Africa cell and gene therapy market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by Middle East and Africa cell and gene therapy manufacturers?
• What is the current and future Middle East and Africa cell and gene therapy market size?
• What is the CAGR of Middle East and Africa cell and gene therapy market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Complementary Benefits

• Complimentary Excel Data Packs Covering All Analytical Modules
• Up to 15% Complimentary Content Customization
• In-Depth Report Walkthrough with the Research Team
• Complimentary Report Update if the Report is 6+ Months Old

This product will be delivered within 5-7 business days.